БИОМАРКЕРЫ ПРИ ЗАБОЛЕВАНИЯХ СУСТАВОВ, СОСТОЯНИЕ ПРОБЛЕМЫ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ

1. <div><p>Jain K.K. Personalized clinical laboratory diagnostics. Adv Clin Chem 2009; 47: 95-119.</p><p>Keeling S.O., Landewe R., van der Heijde D. et al. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. J Rheumatol 2007; 34(3): 623—33.</p><p>Forslind K., Ahlmen M., Eberhardt K. et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63(9): 1090—5.</p><p>Taylor P., Gartemann J., Hsieh J. et al. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011; 2011: 815038(on line).</p><p>Berglin E., Johansson T., Sundin U. et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006; 65(4): 453—8.</p><p>Gilliam B.E., Chauhan A.K., Low J.M. et al. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exper Rheum 2008; 26(3): 492—7.</p><p>Lindqvist E., Eberhardt K., Bendtzen K. et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64(2): 196—201.</p><p>Henrotin Y. Osteoarthritis year 2011 in review: biochemical markers of osteoarthritis: an overview of research and initiatives OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2012, Jan 13 [Epub. ahead of print].</p><p>Garnero P., Ayral X., Rousseau J.C. et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthr Rheum 2002; 46(10): 2613—24.</p><p>Maksymowych W.P., Landewe R., Boers M. et al. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. J Rheumatol 2007; 34(3): 634-40.</p><p>Karsdal M.A., Woodworth T., Henriksen K. et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis — current and future applications, limitations and opportunities. Arthr Res Ther 2011; 13(2): 215.</p><p>Garnero P., Delmas P.D. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr Opin Rheum 2004; 16(4): 428-34.</p><p>Kaneko M., Tomita T., Nakase T. et al. Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology 2001; 40(3): 247—55.</p><p>Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheum Reports 2006; 8(1): 37-44.</p><p>Lories R.J., Luyten F.P., de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthr Res Ther 2009; 11(2): 221.</p><p>Syversen S.W., Goll G.L., van der Heijde D. et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69(2): 345—51.</p><p>Tchetina E.V. Developmental mechanisms in articular cartilage degradation in osteoarthritis. Arthritis 2011; 2011: 683970.</p><p>Goldring S.R. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol 2002; 65(Suppl.): 44—8.</p><p>O'Gradaigh D., Ireland D., Bord S., Compston J.E. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004; 63(4): 354-9.</p><p>Gravallese E.M. Bone destruction in arthritis. Ann Rheum Dis 2002; 61(Suppl. 2): ii84—ii86.</p><p>Pruijn G.J., Wiik A., van Venrooij W.J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthr Res Ther 2010; 12(1): 203.</p><p>Hogue J.H., Mersfelder T.L. Pathophysiology and first-line treatment of osteoarthritis. Ann Pharmacother 2002; 36(4): 679—86.</p><p>Garnero P., Delmas P.D. Biomarkers in osteoarthritis. Curr Opin Rheum 2003; 15(5): 641 —6.</p><p>Wollheim F.A. Early stages of osteoarthritis: the search for sensitive predictors. Ann Rheum Dis 2003; 62(11): 1031—2.</p><p>Thonar E.J., Glant T. Serum keratan sulfate — a marker of predisposition to polyarticular osteoarthritis. Clin Biochem 1992; 25(3): 175—80.</p><p>Sarkozi A.M., Hamori G., Fulop C. et al. Serum keratan sulfate studies and their significance in the evaluation of cartilage degradation in degenerative and inflammatory joint diseases. Orvosi hetilap 1993 28; 134(9): 461—7.</p><p>Wakitani S., Nawata M., Kawaguchi A. et al. Serum keratan sulfate is a promising marker of early articular cartilage breakdown. Rheumatology 2007; 46(11): 1652—6.</p><p>Rousseau J.C., Delmas P.D. Biological markers in osteoarthritis. Nat Clin Pract Rheum 2007; 3(6): 346—56.</p><p>Cibere J., Zhang H., Garnero P. et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthr Rheum 2009; 60(5): 1372—80.</p><p>Hunter D.J., Li J., LaValley M. et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthr Res Ther 2007; 9(5): 108.</p><p>Blumenkrantz G., Majumdar S. Quantitative magnetic resonance imaging of articular cartilage in osteoarthritis. Eur Cell Mater 2007; 13: 76-86.</p><p>Kong S.Y., Stabler T.V., Criscione L.G. et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthr Rheum 2006; 54(8): 2496-504.</p><p>Roos H., Dahlberg L., Hoerrner L.A. et al. Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 1995; 3(1): 7—14.</p><p>Mundermann A., Dyrby C.O., Andriacchi T.P., King K.B. Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2005; 13(1): 34-8.</p><p>Nicklas B.J., Ambrosius W., Messier S.P. et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr 2004; 79(4): 544-51.</p><p>Bauer D.C., Hunter D.J., Abramson S.B. et al. Classification of osteoarthritis biomarkers: a proposed approach. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2006; 14(8): 723-7.</p><p>Henrotin Y., Addison S., Kraus V., Deberg M. Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheum 2007; 19(5): 444-50.</p><p>Kraus V.B., Kepler T.B., Stabler T. et al. First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis. PLoS One 2010; 5(3): e9739.</p><p>Richette P., Poitou C., Garnero P. et al. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis 2011; 70(1): 139-44.</p><p>Gill R.S., Al-Adra D.P., Shi X. et al. The benefits of bariatric surgery in obese patients with hip and knee osteoarthritis: a systematic review. Obes Rev 2011; 12(12): 1083-9.</p><p>Meulenbelt I. Osteoarthritis year 2011 in review: genetics. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2012; Jan 14 [Epub. ahead of print].</p><p>Ishiguro N., Ito T., Oguchi T. et al. Relationships of matrix metal-loproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthr Rheum 2001; 44(11): 2503—11.</p><p>Maleki-Fischbach M., Jordan J.M. New developments in osteoarthritis. Sex differences in magnetic resonance imaging-based biomarkers and in those of joint metabolism. Arthr Res Ther 2010; 12(4): 212.</p><p>Chen H.C., Shah S., Stabler T.V. et al. Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2008; 16(9): 1054-9.</p><p>Henrotin Y., Gharbi M., Deberg M. et al. Fibulin-3 fragments (Fib3-1 and Fib3-2) are potential new biomarkers for the diagnosis of osteoarthritis. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2011; 19(Suppl. 1): 79.</p><p>Meulenbelt I., Kraus V.B., Sandell L.J., Loughlin J. Summary of the OA biomarkers workshop 2010 - genetics and genomics: new targets in OA. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2011; 19(9): 1091-4.</p><p>Kraus V.B., Huebner J.L., DeGroot J., Bendele A. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the guinea pig. OARS, Osteoarthritis Research Society. Osteoarthr Cartilage 2010; 18(Suppl. 3): 35—52.</p><p>Landewe R., van der Heijde D., Klareskog L. et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthr Rheum 2006; 54(10): 3119—25.</p><p>Garnero P., Gineyts E., Christgau S. et al. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthr Rheum 2002; 46(1): 21—30.</p><p>Garnero P., Landewe R., Boers M. et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression ofjoint damage in patients with early rheumatoid arthritis: the COBRA study. Arthr Rheum 2002; 46(11): 2847—56.</p><p>Landewe R., Geusens P., Boers M. et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthr Rheum 2004; 50(5): 1390—9.</p><p>Verstappen S.M., Poole A.R., Ionescu M. et al. Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthr Res Ther 2006; 8(1): 31.</p><p>Mansson B., Carey D., Alini M. et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Investig 1995; 95(3): 1071—7.</p><p>Syversen S.W., Goll G.L., van der Heijde D. et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheum 2009; 36(2): 266—72.</p><p>Mullan R.H., Matthews C., Bresnihan B. et al. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthr Rheum 2007; 56(9): 2919—28.</p><p>Fraser A., Fearon U., Billinghurst R.C. et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthr Rheum 2003; 48(11): 3085—95.</p><p>Ritchlin C.T., Qureshi A.A., de Vlam K. et al. Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheum 2010; 37(2): 462—7.</p><p>Dalbeth N., Pool B., Smith T. et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthr Res Ther 2010; 12(4): 164.</p><p>Hofbauer L.C., Schoppet M., Christ M. et al. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology 2006; 45(10): 1218—22.</p><p>Mease P.J., Antoni C.E., Gladman D.D., Taylor W.J. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64(Suppl. 2): 49—54.</p><p>Coates L.C., Mumtaz A., Helliwell P.S. et al. Development of a disease severity and responder index for psoriatic arthritis (PsA) — report of the OMERACT 10 PsA special interest group. J Rheum 2011; 38(7): 1496—501.</p><p>Skoumal M., Haberhauer G., Fink A. et al. Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? Clin Exper Rheumatol 2008; 26(6): 1087—90.</p><p>Maksymowych W.P., Fitzgerald O., Wells G.A. et al. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009; 36(8): 1792—9.</p><p>Maksymowych W.P., Landewe R., Tak P.P. et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheum 2009; 36(8): 1785—91.</p><p>Franck H., Meurer T., Hofbauer L.C. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheum 2004; 31(11): 2236—41.</p><p>Han C., Robinson D.W. Jr, Hackett M.V. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheum 2006; 33(11): 2167—72.</p><p>Peters M.J., Symmons D.P., McCarey D. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69(2): 325—31.</p><p>Strober B., Teller C., Yamauchi P., Miller J.L. et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Brit J Dermatol 2008; 159(2): 322—30.</p><p>Chen Y.J., Wu C.Y., Shen J.L. et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144(12): 1571—5.</p><p>Cohen A.D., Sherf M., Vidavsky L. et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216(2): 152—5.</p><p>Vanuzzo D., Pilotto L., Mirolo R., Pirelli S. Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation. G Ital Cardiol (Rome) 2008; 9(4 Suppl. 1): 6—17.</p><p>Hulsmans M., Geeraert B., de Keyzer D. et al. Interleukin-1 receptor-associated kinase-3 is a key inhibitor of inflammation in obesity and metabolic syndrome. PLoS One 2012; 7(1): 30414.</p><p>Husted J.A., Thavaneswaran A., Chandran V. et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthr Care Res 2011; 63(12): 1729—35.</p><p>Poole C.D., Conway P., Currie C.J. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology 2009; 48(1): 78—82.</p><p>Martinez V.B., Gonzalez-Juanatey J.R. Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination. Am J Cardiovasc Drugs 2009; (9 Suppl. 1): 3—7.</p></div><br />